Congress sub­poe­nas Shkreli, but he may refuse to tes­tify

Modern Healthcare - - THE WEEK AHEAD - —Shan­non Much­more

The former phar­ma­ceu­ti­cal ex­ec­u­tive who un­apolo­get­i­cally raised the price of a pre­scrip­tion drug from $13.50 a pill to $750 a pill overnight has been sub­poe­naed to ap­pear Tues­day be­fore Congress.

Martin Shkreli could refuse to tes­tify by in­vok­ing the Fifth Amend­ment. He’s al­ready done so to avoid turn­ing over doc­u­ments sub­poe­naed by another con­gres­sional com­mit­tee in­ves­ti­gat­ing high pre­scrip­tion drug prices. He has been flip­pant about the scru­tiny, say­ing he is act­ing as a good busi­ness­man.

The move to raise the price of Dara­prim, a more than 60-year-old drug that treats tox­o­plas­mo­sis, and sim­i­lar de­ci­sions by other drug­mak­ers, have sparked pub­lic out­rage and calls to con­trol sky­rock­et­ing drug prices.

“I have been try­ing for the bet­ter part of a year to get in­for­ma­tion from Martin Shkreli about his out­ra­geous price in­creases, and he has ob­structed our in­ves­ti­ga­tion at ev­ery turn,” the House Over­sight Com­mit­tee’s rank­ing mem­ber, Eli­jah Cum­mings (D-Md.), said in a state­ment. “He claims pub­licly that he wants to ex­plain to Congress how drug pric­ing works. On Tues­day, he will get his chance.”

Also sched­uled to ap­pear be­fore the House Over­sight Com­mit­tee are the in­terim CEO of Valeant Phar­ma­ceu­ti­cals and the chief com­mer­cial of­fi­cer of Shkreli’s former com­pany, Tur­ing Phar­ma­ceu­ti­cals.

Shkreli re­signed as head of Tur­ing af­ter his De­cem­ber ar­rest on charges of se­cu­rity fraud when he was with a dif­fer­ent phar­ma­ceu­ti­cal com­pany. He posted a copy of the sub­poena on his Twit­ter ac­count, with the text: “Found this let­ter. Looks im­por­tant.”

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.